Blockade of ccl18 signaling via ccr6 as a therapeutic option in fibrotic diseases and cancer

a fibrotic disease and cancer technology, applied in the field of ccr6 receptor polypeptide isolation, can solve the problems of irreversible lung damage, poorly understood molecular mechanisms driving their pathogenesis, and elusive etiology of said diseases, and achieve the effect of significantly increasing the percentage of lymphocytes

Inactive Publication Date: 2013-05-02
UNIVERSITATSKLINIKUM FREIBURG
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0075]FIG. 21 Percentage of lymphocytes in BAL from sCCR6 positive and sCCR6 negative controls and (UIP) patients. The percentage of

Problems solved by technology

The aetiology of said diseases has remained elusive and the molecular mechanisms driving their pathogenesis are poorly understood.
Said symptoms often don't appear until the disease is advanced, and irreversible lung damage has already occurred.
The prognosis of IPF is rather poor with an average survival time of 3 years from the time of diagnosis.
At present no effective treatments and no cure for pulmonary fibrosis are available.
Often treatment is limited to treating the inflammatory response that occurs in the lungs.
IPF, however, is refractory to most of these therapeutic options.
Experimental therapy studies using IFNγ, Bosentan® (endothelin antagonist), Aviptadil® (vasoactive intestinal peptide, VIP) or the tyrosine kinase inhibitor Imat

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Blockade of ccl18 signaling via ccr6 as a therapeutic option in fibrotic diseases and cancer
  • Blockade of ccl18 signaling via ccr6 as a therapeutic option in fibrotic diseases and cancer
  • Blockade of ccl18 signaling via ccr6 as a therapeutic option in fibrotic diseases and cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

Materials and Methods

Phage Display Library

[0503]For the identification of a CCL18-binding motif an established phage-display library was used (1).

Cells and Cell Lines

[0504]Fibroblast lines were established either from surgical material from pneum-ectomies or lobe-ectomies from patients suffering from various tumours or from remaining material obtained from fibrotic lungs by video-assisted thoracoscopies (VATS). The patients suffered either from adenocarcinoma of the lung, non-small cell carcinoma or squamous carcinoma. Fibrosis resulted from idiopathic pulmonary fibrosis (UIP), non-specific interstitial pneumonia, sarcoidosis, hypersensitivity pneumonitis, pneumoconiosis or systemic scleroderma. The tissue was cut in small peaces (app. 0.5 cm edge length) and placed in 6-well plates containing 1 ml Quantum 333 (PAA, Pasching, Austria) with 1% penicillin / streptomycin. Outgrowing fibroblasts were harvested when they reached approximately 80% confluence by trypsinisation, cultured in 7...

example 2

Identification of a CCL18-Binding Peptide Using Phage Display

[0540]After 3 circles of binding of the phages of the phage library (as described in Example 1) to plate-bound human CCL18, phage-infected E. coli were plated on agar and 20 colonies were picked, expanded and DNA was isolated for sequencing. Some of the sequences were not informative or coded for non-human gene targets, however, one sequence with a clear relation to the CC-chemokine receptor 6 (CCR6) was identified.

example 3

Analysis of CCR6 Expression On Primary Human Fibroblast Line

PCR

[0541]Expression studies using primers for CCR6 revealed a high variability of CCR6 mRNA expression. Highest expression was found in fibroblast lines derived from lung of patients suffering from usual interstitial pneumonia (UIP). Lines derived from patients suffering from non-specific interstitial pneumonia (NSIP) or squamous carcinoma expressed only marginal levels of CCR6 mRNA (FIG. 1).

FACS

[0542]Flow-cytometric analyses of the established fibroblast lines revealed detectable CCR6 expression only on fibroblast lines derived from patients suffering from UIP. Lines generated from lungs of patients suffering from squamous carcinoma or NSIP do not express detectable CCR6 on their surface (FIG. 2). Increased CCR6 expression of fibroblasts from fibrotic lungs remained increased throughout all passages (data not shown).

Immunohistochemistry

[0543]Immunohistochemical studies on tissue sections taken from lungs of patients with I...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Login to view more

Abstract

The present invention relates to an isolated soluble CCR6 receptor polypeptide capable of binding to CCL18 and/or CCL20 and to a method for quantifying the concentration of a soluble CCR6 receptor polypeptide in a liquid sample from a subject. The present invention also relates to a method for detecting and/or prognosticating an interstitial lung disease or a cancer in a subject by determining the level of a soluble CCR6 receptor polypeptide in a sample from said subject and further provides a pharmaceutical composition comprising a compound capable of inhibiting the activity and/or the expression of CCL18 or CCL20 for the treatment of said diseases. The present invention further relates to an isolated polypeptide capable of binding to and inhibiting the activity of the chemokine receptor CCR6 and to a method for identifying further inhibitors of CCR6 receptor activity. The present invention also relates to a method for detecting an interstitial lung disease or a cancer in a subject by determining the level of CCR6 gene expression in a sample from said subject and further provides pharmaceutical compositions comprising inhibitors of CCR6 receptor activity and/or expression for the treatment of said diseases.

Description

FIELD OF THE INVENTION[0001]The present invention relates to an isolated soluble CCR6 receptor polypeptide capable of binding to CCL18 and / or CCL20 and to a method for quantifying the concentration of a soluble CCR6 receptor polypeptide in a liquid sample from a subject. The present invention also relates to a method for detecting and / or prognosticating an interstitial lung disease or a cancer in a subject by determining the level of a soluble CCR6 receptor polypeptide in a sample from said subject and further provides a pharmaceutical composition comprising a compound capable of inhibiting the activity and / or the expression of CCL18 or CCL20 for the treatment of said diseases. The present invention further relates to an isolated polypeptide capable of binding to and inhibiting the activity of the chemokine receptor CCR6 and to a method for identifying further inhibitors of CCR6 receptor activity. The present invention also relates to a method for detecting an interstitial lung dise...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/715A61K45/06A61K38/16A61K38/17C07K14/00
CPCA61K9/0019A61K38/00C07K14/7158G01N33/57423G01N33/6863G01N2333/521C07K14/00G01N2500/02G01N2800/12A61K38/16A61K38/1793A61K45/06G01N2333/7158A61P1/04A61P1/16A61P11/00A61P13/08A61P13/12A61P15/00A61P35/00A61P43/00C07K14/47C07K16/24C07K16/2866C12N15/1136C12N15/1138C12N15/115C12N2310/11C12N2310/14C12N2310/16
Inventor ZISSEL, GERNOTMULLER-QUERNHEIM, JOACHIMPRASSE, ANTJE
Owner UNIVERSITATSKLINIKUM FREIBURG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap